Acologix Gives Presentation at 2007 BIO Investor Forum

HAYWARD, Calif. – October 10, 2007 – Acologix, Inc., a privately held biopharmaceutical company, today announced that Yoshi Kumagai, President and Chief Executive Officer of Acologix, Inc. presented a overview of the Company’s clinical development programs and product pipeline at the 2007 BIO Investor Forum on Wednesday, October 10, 2007. The conference was held at The Palace Hotel in San Francisco.

Acologix, Inc.

Acologix, Inc. a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnered with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (TRK-820) for the treatment of uremic pruritus in dialysis patients. Acologix is preparing for a Phase III study with this compound for uremic pruritus in the United States for 2008. AC-100 (Dentonin^®), a novel small peptide with dental, periodontal and orthopedic applications, has been studied in two Phase II clinical studies; one in dental restoration procedures and another for the repair of periodontal defects. Further studies to support development in orthopedic indications are ongoing. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease. For more information, go to www.acologix.com.

This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix’ business.

Acologix Contact

Yoshi Kumagai
President and CEO
Phone: 510-512-7200
Fax: 510-786-1116
ir-usa@acologix.com